BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial

ConditionDry Eye Disease

Trial statusNot yet recruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18+

SponsorBausch & Lomb Incorporated

About this trial

Trial RX01-BL1107-1202 is designed to identify the lowest effective concentration of BL1107 required for complete resolution of conjunctival hyperemia in participants with DED. Participants will be masked to concentration of BL1107 received.

Eligibility criteria

Qualifiers

Documented diagnosis of dry eye disease

Conjunctival hyperemia in both eyes, without clinical signs of infection or allergic conjunctivitis

Disqualifiers

Any active ocular disease

Anticipated wearing of contact lenses during study

Trial design

Treatments tested in this trial

BL1107

Treatment groups

20 Participants

are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators

Bausch & Lomb Incorporated

Lead sponsor

Source ClinicalTrials.gov